Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients

Prostate Cancer and Prostatic Diseases volume 10, pages 293–300 (2007)Cite this article

Abstract

Anterior gradient-2 (AGR2) expression was examined in a series of prostate cell lines and in an archival set of prostate tissues. The relative levels of AGR2 expression in the malignant cell lines PC-3 and PC-3M were, respectively, 5.3±0.1 and 3.8±0.2 times that detected in the benign cell line PNT-2. Immunohistochemical staining in 106 cases showed that amongst seven normal cases, one (14.3%) was unstained, five (71.4%) stained weakly positive and one (14.3%) stained moderately positive. Amongst 34 benign prostate hyperplastic (BPH) cases, 12 (35.3%) were unstained, 18 (52.9%) stained weakly positive and four (11.8%) stained moderately positive. Amongst 65 carcinomas, three (4.6%) were unstained, 14 (21.5%) stained weakly positive, 19 (29.2%) stained moderately positive and 29 (44.9%) stained strongly positive. AGR2 expression in carcinomas was significantly higher than that in BPH (χ2-test, P<0.001). Kaplan–Meier survival analysis showed that increased AGR2 expression was significantly (log rank test, P=0.007) associated with reduced patient-survival time. Increased joint Gleason score (GS) was significantly (log rank test, P=0.001) associated with poor patient survival. However, neither prostate specific antigen (PSA) level, nor androgen receptor (AR) index, was significantly associated with patient-survival time. Increased AGR2 expression was significantly correlated with high GS (two-sided Fisher's exact test, P<0.001) and PSA levels (Mann–Whitney U-test, P=0.047), but not significantly related to the level of AR (Mann–Whitney U-test, P=0.286). These results suggest that increased AGR2 expression is a valuable prognostic factor to predict the clinical outcome of the prostate cancer patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Tarassoff CP, Arlen PM, Gulley JL . Therapeutic vaccines for prostate cancer. Oncologist 2006; 11: 451–462.

    Article  CAS  Google Scholar 

  2. Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics. CA Cancer J Clin 1999; 41: 8–31.

    Article  Google Scholar 

  3. Foster CS, Cornford P, Forsyth L, Djamgoz MB, Ke Y . The cellular and molecular basis of prostate cancer. BJU Int 1999; 83: 171–194.

    Article  CAS  Google Scholar 

  4. Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A et al. Cancer statistics. CA Cancer J Clin 2005; 55: 10–30.

    Article  Google Scholar 

  5. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J . Molecular pathology of prostate cancer. J Clin Pathol 2005; 58: 673–684.

    Article  CAS  Google Scholar 

  6. Jing C, Beesley C, Foster C, Chen H, Rudland P, West D et al. Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. Cancer Res 2001; 61: 4357–4364.

    CAS  PubMed  Google Scholar 

  7. Jing C, El-Ghany M, Beesley C, Foster C, Rudland P, Smith P et al. Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to the tumorigenicity. J Natl Cancer Inst 2002; 94: 482–490.

    Article  CAS  Google Scholar 

  8. May F, Hartung R, Breul J . The ability of the American Joint Committee on Cancer Staging System to predict progression-free survival after radical prostatectomy. BJU Int 2001; 88: 702–707.

    Article  CAS  Google Scholar 

  9. Thompson DA, Weigel RJ . hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun 1998; 251: 111–116.

    Article  CAS  Google Scholar 

  10. Komiya T, Tanigawa Y, Hirohashi S . Cloning of the gene gob-4, which is expressed in intestinal goblet cells in mice. Biochim Biophys Acta 1999; 1444: 434–438.

    Article  CAS  Google Scholar 

  11. Aberger F, Weidinger G, Grunz H, Richter K . Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech Dev 1998; 72: 115–130.

    Article  CAS  Google Scholar 

  12. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R . Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005; 65: 3796–3805.

    Article  CAS  Google Scholar 

  13. Innes H, Liu D, Barraclough R, Davies M, O'Neill P, Platt-Higgins A et al. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer 2006; 94: 1057–1065.

    Article  CAS  Google Scholar 

  14. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY . AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005; 43: 249–259.

    Article  CAS  Google Scholar 

  15. Cussenot O, Berthon P, Berger R, Mowszowicz I, Faille A, Hojman F et al. Immortalization of human adult normal prostatic epithelial cells by liposomes containing Large T-SV40 gene. J Urol 1991; 143: 881–886.

    Article  Google Scholar 

  16. Berthon P, Cussenot O, Hopwood L, Le Duc A, Matkland N . Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: differentiation pattern of non-tumorigenic cell lines. Int J Oncol 1995; 6: 333–343.

    CAS  Google Scholar 

  17. Horoszewicz JS, Leong S, Kawinski E, Karr J, Rosenthal H, Chu T et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809–1818.

    CAS  Google Scholar 

  18. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF . Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer 1978; 21: 274–281.

    Article  CAS  Google Scholar 

  19. Kaighn ME, Lechner JF, Narayan KS, Jones LW . Prostate carcinoma: tissue culture cell lines. Natl Cancer Inst Monogr 1978; 49: 17–21.

    Google Scholar 

  20. Ke Y, Jing C, Barraclough R, Smith P, Davies MP, Foster CS . Elevated expression of calcium-binding protein p9Ka is associated with increasing malignant characteristics of rat prostate carcinoma cells. Int J Cancer 1997; 71: 827–837.

    Article  Google Scholar 

  21. Deshmukh N, Scotson J, Dodson AR, Smith PH, Ke Y, Forster CS . Differential expression of acidic and basic fibroblast growth factors in benign prostatic hyperplasia identified by immunohistochemistry. Br J Urol 1997; 80: 869–874.

    Article  CAS  Google Scholar 

  22. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006; 118: 2255–2261.

    Article  CAS  Google Scholar 

  23. Gleason DF, Mellinger GT . Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58–64.

    Article  CAS  Google Scholar 

  24. Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H . Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1–10 ng/ml. Urology 2003; 61: 760–764.

    Article  Google Scholar 

  25. Remmele W, Stegner HE . Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathology 1987; 8: 138–140.

    CAS  Google Scholar 

  26. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP . Prostatic intraepithelial neoplasia in mice expression an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 2001; 98: 10823–10828.

    Article  CAS  Google Scholar 

  27. Kuang WW, Thompson DA, Hoch RV, Weigel RJ . Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. Nucleic Acids Res 1998; 26: 1116–1123.

    Article  CAS  Google Scholar 

  28. Fletcher GC, Patel S, Tyson K, Adam P, Schenker M, Loader J et al. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J cancer 2003; 88: 579–585.

    Article  CAS  Google Scholar 

  29. Fritzsche F, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E et al. Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res 2006; 12: 1728–1734.

    Article  CAS  Google Scholar 

  30. Zheng W, Rosenstiel P, Huse K, Sina C, Valentonyte R, Mah N et al. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun 2006; 7: 11–18.

    Article  CAS  Google Scholar 

  31. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005; 205: 359–376.

    Article  CAS  Google Scholar 

  32. Adamson J, Morgan E, Beesley C, Mei Y, Forster C, Fujii H et al. High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene 2003; 22: 2739–2749.

    Article  CAS  Google Scholar 

  33. Smith P, Rhodes N, Ke Y, Foster C . Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS lett 1998; 423: 19–24.

    Article  CAS  Google Scholar 

  34. Collette L, Burzykowski T, Schroder FH . Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006; 42: 1344–1350.

    Article  Google Scholar 

  35. Freedland SJ, Partin AW . Prostate-specific antigen: update 2006. Urology 2006; 67: 458–460.

    Article  Google Scholar 

  36. Shah RB, Mehra R, Chinnaiyan A, Shen R, Ghosh D, Zhou M et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64: 9209–9216.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank North West Cancer Research Fund and the USA Army PCRP Fund for their generous support of research grants.

Author information

Authors and Affiliations

  1. Molecular Pathology Laboratory, School of Cancer Studies, The University of Liverpool, Liverpool, UK

    Y Zhang, S S Forootan, C S Foster & Y Ke

  2. Cancer Tissue Bank Research Centre, The University of Liverpool, Liverpool, UK

    D Liu

  3. School of Biological Sciences, The University of Liverpool, Liverpool, UK

    R Barraclough & P S Rudland

Authors
  1. Y Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S S Forootan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Barraclough
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C S Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P S Rudland
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S S Forootan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, Y., Forootan, S., Liu, D. et al. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 10, 293–300 (2007). https://doi.org/10.1038/sj.pcan.4500960

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500960

Keywords

This article is cited by

Search

Advanced search

Quick links